Skip to content

Performance comparison between ECG-gated 7 Tesla and clinical 1.5 Tesla Cardiac Magnetic Resonance Imaging in patients with cardiac scar tissue

7 Tesla UltraHigh Field ECG-gated Cardiac Magnetic Resonance Imaging in non-stented patients with cardiac scar tissue, for left ventricular (LV) and right ventricular (RV) volumetric assessment and scar quantitation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616001484437
Enrollment
10
Registered
2016-10-25
Start date
2017-01-09
Completion date
2017-02-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The research project proposed is to develop cardiac magnetic resonance imaging (CMRI) techniques currently used at standard magnetic field strengths (1.5 or 3 Tesla) for significantly higher field strengths at 7 Tesla (7T). The aims are as follows: 1. To valuate the performance of 7T CMRI compared with standard clinical CMRI at 1.5T. 2. To determine whether 7T CMRI can provide adequate images to measure heart function and cardiac scar imaging. Methods: Participants will be recruited from patients with cardiac scar tissue undergoing routine clinical CMRI with gadolinium contrast agent at 1.5T. All recruited subjects will have an additional 7T CMRI with gadolinium contrast agent. CMRI is a painless, non-invasive test that involves lying in a scanner for a duration of approximately 1 hr. The results of the clinical 1.5T CMRI scan and the experimental 7T CMRI scan will be compared.

Interventions

7 Tesla (7T) Ultra-High Field Cardiac Magnetic Resonance Imaging (CMRI) Participants will be recruited from patients with cardiac scar tissue undergoing routine clinical CMRI with gadolinium contrast agent at 1.5 Tesla. All recruited subjects will have an additional 7T CMRI with gadolinium contrast agent. CMRI is a painless, non-invasive test that involves lying in a scanner. Each patient will first undergo one 1.5T scan of approximately 1 hour duration as part of their normal clinical care. Wit

7 Tesla (7T) Ultra-High Field Cardiac Magnetic Resonance Imaging (CMRI) Participants will be recruited from patients with cardiac scar tissue undergoing routine clinical CMRI with gadolinium contrast agent at 1.5 Tesla. All recruited subjects will have an additional 7T CMRI with gadolinium contrast agent. CMRI is a painless, non-invasive test that involves lying in a scanner. Each patient will first undergo one 1.5T scan of approximately 1 hour duration as part of their normal clinical care. Within 4 weeks of their clinical scan, consenting participants will be asked to come to the imaging facility at The Centre for Advanced Imaging, The University of Queensland. There they will undergo one additional 7T CMRI scan of approximately 1 hour duration. The results of the clinical 1.5T CMRI scan and the experimental 7T CMRI scan will be compared to 1. evaluate the performance of 7T CMRI compared with standard CMRI at 1.5 T. 2. determine whether 7T CMRI can provide adequate images to measure heart function and scar tissue imaging.

Sponsors

The University of Queensland
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Intervention model
Crossover
Primary purpose
Diagnosis

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients scheduled for a clinical CMRI on 1.5T MR scanner, having scar tissue from a prior myocardial infarct (MI) or a non-ischaemic myocardial injury (such as HCM, myocarditis or sarcoid)

Exclusion criteria

(1) Subject has MRI non-conditional metal implant, such as a pacemaker (2) Subject has significant kidney impairment; (3) Subject has coronary artery stent implanted; (4) Subject has severe allergy to Gadolinium (Gd) contrast agent; (5) Subject has claustrophobia; (6) Subject is pregnant or breastfeeding; (7) Subject is less than 18 years old.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026